Bengaluru-based CURAPOD, backed by Litemed India Private Limited, has raised Rs 20 crore in a Pre-Series A funding round led by V3 Ventures, 3i Partners and Ideaspring Capital.
The fundraise reflects growing investor confidence in the company’s non-invasive, personalised pain management wearable aimed at addressing the high prevalence of musculoskeletal disorders.
The capital infusion will be used to accelerate product and mobile application upgrades, strengthen branding and marketing initiatives, expand direct-to-consumer sales through online marketplaces, and deepen partnerships with gyms, physiotherapy clinics and sports medicine networks. CURAPOD also plans to scale manufacturing capacity and strengthen its go-to-market operations. The company expects the investment to improve operational efficiencies, strengthen unit economics and support a targeted five-fold revenue growth over the next 12 months.
A portion of the funding will also be deployed towards international expansion, with Europe identified as a key priority market. Preparations for overseas entry include regulatory readiness, expansion of clinical evidence and development of local market infrastructure, according to the company.
CURAPOD offers a clinically validated, non-invasive pain relief device that uses photobiomodulation therapy, including targeted red light wavelengths, to deliver personalised pain management. The technology works at the cellular level to reduce inflammation, improve blood circulation and support tissue repair, enabling pain relief for many users with consistent daily use of 30 to 60 minutes.
The FDA-registered device is designed to support more than 30 musculoskeletal conditions, including back, neck and knee pain, joint disorders, muscle stiffness, sports injuries, chronic injuries and post-activity recovery. Positioned as a drug-free alternative to conventional pain management, the device combines medical-grade engineering with everyday usability.
Investors highlighted the scale of the pain management market and the company’s differentiated approach through wearable, clinically backed technology. CURAPOD’s leadership said the funding will support deeper clinical engagement, continued product innovation and wider access to personalised pain management solutions, while enabling expansion across manufacturing, supply chain, talent acquisition and nationwide distribution.
Ideaspring Capital, an early backer of Litemed, said the investment aligns with its long-term view of building a broader portfolio of light-therapy-based pain relief devices as part of the company’s future roadmap.
